RCM
LMDXW

Radcliffe Capital Management’s LumiraDx Limited Warrant LMDXW Stock Holding History

Radcliffe Capital Management’s Portfolio LMDXW Stock Details LMDXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$827K – 1082
2021
Q3 		$827K Buy
+100,000
New +$116K 0.02% 755

Other funds holding LMDXW

CH
CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $64K AUM
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Radcliffe Capital Management's LMDXW Position: Q4 2021 in Review

Radcliffe Capital Management sold out of LumiraDx Limited Warrant (LMDXW) in Q4 2021, closing a stake of 100,000 shares — an estimated $827K sold.

Radcliffe Capital Management first reported a position in LMDXW in Q3 2021 and held it in 1 quarter. The position peaked at $827K in Q3 2021. 24 funds tracked by Wall St. Rank hold LMDXW as of Q4 2021.

  • Radcliffe Capital Management reported no remaining LumiraDx Limited Warrant position as of Q4 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 100,000 LumiraDx Limited Warrant shares in Q4 2021, an estimated $827K.
  • Radcliffe Capital Management first reported a position in LumiraDx Limited Warrant in Q3 2021 and held it in 1 quarter.
  • Radcliffe Capital Management's LumiraDx Limited Warrant position peaked at $827K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q4 2021.

Based on Radcliffe Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.